Histological improvement in chronic hepatitis C-autoimmune hepatitis overlap syndrome by glecaprevir and pibrentasvir.
Autoimmune hepatitis
Glecaprevir/pibrentasvir
Hepatitis C
Overlap syndrome
Journal
Clinical journal of gastroenterology
ISSN: 1865-7265
Titre abrégé: Clin J Gastroenterol
Pays: Japan
ID NLM: 101477246
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
21
03
2023
accepted:
18
04
2023
medline:
21
7
2023
pubmed:
29
4
2023
entrez:
28
4
2023
Statut:
ppublish
Résumé
A 60-year-old man with type-2 diabetes and chronic hepatitis C (HCV) was diagnosed with single hepatocellular carcinoma (HCC) of 67 mm in the hepatic posterior right lobe. Lenvatinib 8 mg was initiated but discontinued because of grade 3 liver injury. The patient continued to have prolonged liver injury and persistently high immunoglobulin G levels. Antinuclear antibody titer increased from 1:40 to 1:320. Histopathological examination of a liver biopsy specimen revealed interface hepatitis with lymphocyte and plasma cell infiltration, rosette formation, and emperipolesis, suggesting the possibility of autoimmune hepatitis (AIH). First, treatment with prednisolone was initiated; however, the response was poor. After starting glecaprevir/pibrentasvir (GLE/PIB) as direct-acting antivirals (DAA), HCV RNA rapidly disappeared, and serological liver function improved. After confirmation of sustained virological response 24, HCC recurrence was observed, and partial hepatectomy was performed. Background liver findings showed that liver parenchymal inflammation improved compared with that before DAA treatment. This is the first case of HCV-AIH overlap syndrome treated with DAA using GLE/PIB. Liver function improved within a short treatment period of 8 weeks, as confirmed using serology and histology.
Identifiants
pubmed: 37118643
doi: 10.1007/s12328-023-01809-7
pii: 10.1007/s12328-023-01809-7
doi:
Substances chimiques
glecaprevir and pibrentasvir
0
pibrentasvir
2WU922TK3L
Antiviral Agents
0
glecaprevir
K6BUU8J72P
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
572-579Informations de copyright
© 2023. Japanese Society of Gastroenterology.
Références
Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12:671–5.
doi: 10.1002/hep.1840120409
pubmed: 2170265
Rigopoulou EI, Zachou K, Gatselis N, et al. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. Ann Hepatol. 2013;13:127–35.
doi: 10.1016/S1665-2681(19)30914-7
pubmed: 24378276
Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med. 1996;125:588–98.
doi: 10.7326/0003-4819-125-7-199610010-00009
pubmed: 8815758
Kogure T, Ueno Y, Fukushima K, et al. Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferonalpha 2b plus ribavirin treatment. World J Gastroenterol. 2007;13:4394–7.
doi: 10.3748/wjg.v13.i32.4394
pubmed: 17708618
pmcid: 4250871
Sezaki H, Arase Y, Tsubota A, et al. Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy. J Gastroenterol. 2003;38:493–500.
doi: 10.1007/s00535-002-1090-7
pubmed: 12768394
Calleja JL, Albillos A, Cacho G, Iborra J, Abreu L, Escartín P. Interferon and prednisone therapy in chronic hepatitis C with nonorgan-specific antibodies. J Hepatol. 1996;24:308–12.
doi: 10.1016/S0168-8278(96)80009-2
pubmed: 8778197
Sahebjam F, Hajdu CH, Nortey E, et al. Direct acting antiviral therapy is curative for chronic hepatitis C/autoimmune hepatitis overlap syndrome. World J Hepatol. 2016;8:632–6.
doi: 10.4254/wjh.v8.i14.632
pubmed: 27190580
pmcid: 4867421
Sugiura A, Wada S, Mori H, et al. Successful treatment for chronic hepatitis C-autoimmune hepatitis overlap syndrome due to daclatasvir and asunaprevir. Case Rep Gastroenterol. 2017;11:305–11.
doi: 10.1159/000475752
pubmed: 28626376
pmcid: 5471785
Putra J, Schiano TD, Fiel MI. Resolution of HCV-autoimmune hepatitis overlap syndrome with antiviral treatment A paired liver biopsy study. Am J Clin Pathol. 2019;152:735–41.
doi: 10.1093/ajcp/aqz095
pubmed: 31310654
Takikawa H, Onji M. A proposal of the diagnostic scale of drug-induced liver injury. Hepatol Res. 2005;32:250–1.
doi: 10.1016/j.hepres.2005.05.007
pubmed: 16099713
Chrétien P, Chousterman M, Abd Alsamad I, et al. Non-organ-specific autoantibodies in chronic hepatitis C patients: association with histological activity and fibrosis. J Autoimmun. 2009;32:201–5.
doi: 10.1016/j.jaut.2009.02.005
pubmed: 19324518
Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology. 1997;26:459–66.
doi: 10.1002/hep.510260229
pubmed: 9252159
European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63:971–1004.
doi: 10.1016/j.jhep.2015.06.030
Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology. 1992;15:572–7.
doi: 10.1002/hep.1840150403
pubmed: 1551632
Simoes CC, Saldarriaga OA, Utay NS, et al. Direct-acting antiviral treatment of patients with hepatitis C resolves serologic and histopathologic features of autoimmune hepatitis. Hepatol Commun. 2019;3:1113–23.
doi: 10.1002/hep4.1388
pubmed: 31388631
pmcid: 6671831
Enomoto M, Ikura Y, Tamori A, et al. Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C. United Eur Gastroenterol J. 2018;6:1391–400.
doi: 10.1177/2050640618791053
Miyaki E, Imamura M, Hiraga N, et al. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res. 2016;46:756–64.
doi: 10.1111/hepr.12621
Bachofner JA, Valli PV, Kröger A, et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2017;37:369–76.
doi: 10.1111/liv.13256
pubmed: 27678216
Toyofuku T, Hirano K, Ichida T. Clinical significance of M2BPGi measurement in HCV treatment. Jpn J Med Technol. 2017;66:642–8.